Aktienanalyse zu Grail Inc (GRAL)GRALGrail Inc

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).

Grail Inc is a good buy right now due to its recent revenue growth of 25.9% year-over-year, reaching $44.7 million in Q2, and a current price of $80, which is below the analyst target of $88 from TD Cowen. The RSI is at 58.103, indicating a healthy momentum, while the forward P/E ratio is currently at 0, suggesting potential for future profitability as the company seeks FDA approval for its products. However, a key risk is the insider selling, which has increased by 191.52% over the last month, indicating potential concerns about the company's future performance.